Psilocybin
ATMA OFFERS PSYCHEDELIC-ASSISTED THERAPY TRAINING IN AUSTRALIA TO SUPPORT PSYCHIATRISTS AND HEALTHCARE PROFESSIONALS
In response to Australia’s approval of MDMA and psilocybin use in therapy AUSTRALIA, Feb. 7, 2023 /PRNewswire/ — ATMA Journey Centers Inc. (“ATMA”), Canada’s leading…
The post ATMA OFFERS PSYCHEDELIC-ASSISTED THERAPY TRAINING IN AUSTRALIA TO SUPPORT PSYCHIATRISTS AND HEALTHCARE PROFESSIONALS appeared first on ATMA Journey Centers.
psilocybin mdma psychedelic therapy psilocybin-assisted therapy-
Law & Regulation1 week ago
FDA to weigh safety, impact of MDMA therapy for PTSD at June meeting
-
Psychedelics1 week ago
Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University’s Institute for Psychedelic Research
-
Ketamine1 week ago
Clinical-Stage BioTech Drug Stocks Portfolio UP 7% In w/e May 3rd
-
Psychedelics1 week ago
Optimi Health Provides Corporate Update
-
Law & Regulation1 week ago
Horizons talk shifts from investors to insurance
-
Law & Regulation1 week ago
DEA psychedelics ban hearing halted by lawsuit
-
Law & Regulation6 days ago
Relmada loses another $21.8M, makes progress with clinical trials
-
Psychedelics5 days ago
BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001